156 Chapter 7 7.7 REFERENCES 1. Jellinger KA, Attems J. Challenges of multimorbidity of the aging brain: a critical update. J Neural Transm. 2015;122:505–21. 2. Kovacs GG, Milenkovic I, Wöhrer A, et al. Non-Alzheimer neurodegenerative pathologies and their combinations are more frequent than commonly believed in the elderly brain: A community-based autopsy series. Acta Neuropathol. 2013;126:365–84. 3. Gorelick PB, Scuteri A, Black SE, et al. Vascular contributions to cognitive impairment and dementia: A statement for healthcare professionals from the American Heart Association/ American Stroke Association. Stroke. 2011;42:2672–713. 4. Brundel M, Heringa SM, De Bresser J, et al. High Prevalence of Cerebral Microbleeds at 7Tesla MRI in Patients with Early Alzheimer’s Disease. Journal of Alzheimer’s Disease. 2012;31:259–63. 5. Pantoni L. Cerebral small vessel disease: from pathogenesis and clinical characteristics to therapeutic challenges. Lancet Neurol. 2010;9:689–701. 6. Voigt S, Koemans EA, Rasing I, et al. Minocycline for sporadic and hereditary cerebral amyloid angiopathy (BATMAN): study protocol for a placebo-controlled randomized double-blind trial. Trials. 2023;24:1–6. 7. Wardlaw JM, Smith C, Dichgans M. Mechanisms of sporadic cerebral small vessel disease: Insights from neuroimaging. Lancet Neurol. 2013;12:483–97. 8. Bos D, Wolters FJ, Darweesh SKL, et al. Cerebral small vessel disease and the risk of dementia: A systematic review and meta-analysis of population-based evidence. Alzheimer’s and Dementia. 2018;14:1482–92. 9. de Leeuw F ‐E., de Groot JC, Oudkerk M, et al. Hypertension and cerebral white matter lesions in a prospective cohort study. Brain. 2002;125:765–72. 10. Debette S, Markus HS. The clinical importance of white matter hyperintensities on brain magnetic resonance imaging: systematic review and meta-analysis. BMJ. 2010;341:288. 11. Alber J, Alladi S, Bae H, et al. White matter hyperintensities in vascular contributions to cognitive impairment and dementia (VCID): Knowledge gaps and opportunities. Alzheimer’s & Dementia: Translational Research & Clinical Interventions. 2019;5:107–17. 12. De Bresser J, Kuijf HJ, Zaanen K, et al. White matter hyperintensity shape and location feature analysis on brain MRI; Proof of principle study in patients with diabetes. Sci Rep. 2018;8:1–10. 13. Promjunyakul NO, Dodge HH, Lahna D, et al. Baseline NAWM structural integrity and CBF predict periventricular WMH expansion over time. Neurology. 2018;90:e2107–18. 14. Maillard P, Fletcher E, Lockhart SN, et al. White matter hyperintensities and their penumbra lie along a continuum of injury in the aging brain. Stroke. 2014;45:1721–6. 15. Duering M, Csanadi E, Gesierich B, et al. Incident lacunes preferentially localize to the edge of white matter hyperintensities: insights into the pathophysiology of cerebral small vessel disease. Brain. 2013;136:2717–26. 16. Wardlaw JM, Smith C, Dichgans M. Small vessel disease: mechanisms and clinical implications. Lancet Neurol. 2019;18:684–96. 17. Gouw AA, Seewann A, Van Der Flier WM, et al. Heterogeneity of small vessel disease: A systematic review of MRI and histopathology correlations. J Neurol Neurosurg Psychiatry. 2011;82:126–35. 18. Keller JA, Sigurdsson S, Klaassen K, et al. White matter hyperintensity shape is associated with long-term dementia risk. Alzheimer’s and Dementia. 2023;19:5632–5641. 19. Ghaznawi R, Geerlings MI, Jaarsma-Coes M, et al. Association of White Matter Hyperintensity Markers on MRI and Long-term Risk of Mortality and Ischemic Stroke. Neurology. 2021;96:e2172–83.
RkJQdWJsaXNoZXIy MTk4NDMw